
Respiratory decline is a key cause of morbidity and mortality in amyotrophic lateral sclerosis (ALS), and the finding that the calcium sensitizer levosimendan could improve diaphragm function in healthy individuals raised hopes that this drug could preserve respiratory function in people with ALS. However, the phase III REFALS trial, which was recently reported in The Lancet Neurology, showed no beneficial effects of levosimendan on respiratory function in this patient population. Despite these negative findings, the possibility remains that a subgroup of patients with ALS could prove to be responsive to the drug.
Like
Save
Share